Rethinking Pain Management in Psoriatic Arthritis
EULAR 20017: Despite the use of biologic therapy, pain ranging from mild to severe is a persistent problem for psoriatic arthritis patients, researchers reported at EULAR 2017.
Heart Disease in Lupus More Common than Previously Thought
EULAR 2017: Although already known to be highly prevalent, this test reveals that cardiovascular events are even more widespread in lupus.
Heart Disease is Down, Gout is Up, Biosimilars Confuse Patients and more from EULAR 2017
EULAR 2017 wraps on Saturday. In this slideshow, we highlight some of the most popular presentations from the meeting.
Better to Treat Rheumatoid Arthritis in its Early Stages
EULAR 2017: Undifferentiated arthritis or very early rheumatoid arthritis should be treated soon after diagnosis to prevent advanced arthritis.
Romosozumab Continues to Build Bone, Reduce Fracture Risk
EULAR 2017: Romosozumab reduces the risk of clinical vertebral fractures in postmenopausal women with osteoporosis by as much as five times.
Choice of Second-Line Therapy in RA Influenced by MBDA Score
Rheumatoid arthritis patients with lower MBDA scores respond better to triple therapy vs. methotrexate and infliximab combo.
15 Recommendations for Treating Glucocorticoid-Induced Osteoporosis
For the first time in seven years, the ACR has new treatment recommendations for glucocorticoid-induced osteoporosis. In this slideshow, we highlight the new guidelines.
Moderate to Severe Chronic Pain May Signal Early Death
The severity of long-term chronic pain that impedes daily life seems to be associated with higher mortality, researchers report.
Sjogren’s Still an Orphan Disease?
Sjogren’s fails a clinical trial with rituximab and a cost analysis. Even with a significant discount, it’s still not cost effective.
Adalimumab Biosimilar Performs Well in RA Trial
The biosimilar adalimumab-atto is equivalent to its reference product — which it slightly outperformed in this trial.